890 related articles for article (PubMed ID: 26116088)
1. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
2. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Apr; 13(2):238-249. PubMed ID: 29656333
[TBL] [Abstract][Full Text] [Related]
3. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
[TBL] [Abstract][Full Text] [Related]
7. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
9. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
11. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
Front Immunol; 2022; 13():757002. PubMed ID: 35154096
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
Duncan CN; Majhail NS; Brazauskas R; Wang Z; Cahn JY; Frangoul HA; Hayashi RJ; Hsu JW; Kamble RT; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Maziarz RT; Mehta P; Myers KC; Norkin M; Pidala JA; Porter DL; Reddy V; Saber W; Savani BN; Schouten HC; Steinberg A; Wall DA; Warwick AB; Wood WA; Yu LC; Jacobsohn DA; Sorror ML
Biol Blood Marrow Transplant; 2015 Jan; 21(1):151-8. PubMed ID: 25316109
[TBL] [Abstract][Full Text] [Related]
14. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.
Fan S; Pan TZ; Dou LP; Zhao YM; Zhang XH; Xu LP; Wang Y; Huang XJ; Mo XD
Front Immunol; 2023; 14():1091014. PubMed ID: 36817493
[TBL] [Abstract][Full Text] [Related]
15. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
[No Abstract] [Full Text] [Related]
16. IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1303-1310. PubMed ID: 28457953
[TBL] [Abstract][Full Text] [Related]
17. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
18. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
19. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
[TBL] [Abstract][Full Text] [Related]
20. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
